{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ANDREW ROSS SORKIN", "person": [{"middlename": "Ross", "firstname": "Andrew", "lastname": "SORKIN", "rank": 1, "role": "reported", "organization": ""}]}, "abstract": "Andrew Ross Sorkin DealBook column contends activist investor William A Ackman, head of Pershing Square Capital Management, has confounding and sometimes contradictory views on investing; contrasts his crusade against nutritional supplements firm Herbalife and his investment in Valeant, which is under investigation for drug pricing.", "type_of_material": "News", "word_count": "1101", "lead_paragraph": "Bill Ackman has led something of a crusade on moral grounds against Herbalife, a nutritional supplements company, but he seems unperturbed by Valeant&#8217;s rapacious re-pricing of old drugs.", "pub_date": "2015-11-10T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Bill Ackman\u2019s Enigmatic Approach to Valeant Pharmaceuticals", "content_kicker": "DealBook", "print_headline": "Ackman&#8217;s Enigmatic Investment Philosophy ", "kicker": "DealBook Column"}, "snippet": "Bill Ackman has led something of a crusade on moral grounds against Herbalife, a nutritional supplements company, but he seems unperturbed by Valeant&#8217;s rapacious re-pricing of old drugs.", "multimedia": [{"height": 126, "url": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 399, "url": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "399", "xlarge": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/11/10/business/dealbook/ackmans-enigmatic-investment-philosophy.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Ackman, William A", "name": "persons"}, {"rank": "2", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Herbalife Ltd", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Pershing Square Capital Management", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Ethics (Personal)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Stocks and Bonds", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "5641515138f0d80e74ff97e3", "source": "The New York Times"}